We report a patient who achieved hematologic response with Imatinib mesylate and is in chronic phase, but after several years developed neurologic symptoms and was eventually documented to have an isolated CNS relapse. The patient was treated with intrathecal chemotherapy to clear the spinal fluid of the leukemia cells. Imatinib mesylate (STI-571) is a potent and selective inhibitor of BCR-ABL tyrosine kinase and has emerged as a treatment of choice in chronic myeloid leukaemia. However because of poor penetration of the drug to the blood-brain barrier of the central nervous system (CNS), then the CNS acts as a sanctuary site for malignant cells.
Introduction: Myelofibrosis is characterized by bone marrow fibrosis, cytopenias and extramedullary hematopoiesis. Ruxolitinib is a Janus Kinase-2 inhibitor recently approved for myelofibrosis. In the Philippines, it was made available through the compassionate use program.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.